Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature Erickson, A., He, M., Berglund, E., Marklund, M., Mirzazadeh, R., Schultz, N., Kvastad, L., Andersson, A., Bergenstrahle, L., Bergenstrahle, J., Larsson, L., Alonso Galicia, L., Shamikh, A., Basmaci, E., Diaz De Stahl, T., Rajakumar, T., Doultsinos, D., Thrane, K., Ji, A. L., Khavari, P. A., Tarish, F., Tanoglidi, A., Maaskola, J., Colling, R., Mirtti, T., Hamdy, F. C., Woodcock, D. J., Helleday, T., Mills, I. G., Lamb, A. D., Lundeberg, J. 2022; 608 (7922): 360-367

Abstract

Defining the transition from benign to malignant tissue is fundamental to improving early diagnosis of cancer1. Here we use a systematic approach to study spatial genome integrity in situ and describe previously unidentified clonal relationships. We used spatially resolved transcriptomics2 to infer spatial copy number variations in >120,000 regions across multiple organs, in benign and malignant tissues. We demonstrate that genome-wide copy number variation reveals distinct clonal patterns within tumours and in nearby benign tissue using an organ-wide approach focused on the prostate. Our results suggest a model for how genomic instability arises in histologically benign tissue that may represent early events in cancer evolution. We highlight the power of capturing the molecular and spatial continuums in a tissue context and challenge the rationale for treatment paradigms, including focal therapy.

View details for DOI 10.1038/s41586-022-05023-2

View details for PubMedID 35948708